Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual Patient Data Meta-analysis

Christian Mirian, Anne Katrine Duun-Henriksen, Andrea Daniela Maier, Maria Møller Pedersen, Lasse Rehné Jensen, Asma Bashir, Thomas Graillon, Maya Hrachova, Daniela Bota, Martjin van Essen, Petar Spanjol, Christian Kreis, Ian Law, Helle Broholm, Lars Poulsgaard, Kåre Fugleholm, Morten Ziebell, Tina Munch, Martin A Walter, Tiit Mathiesen

42 Citations (Scopus)

Abstract

Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan-Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS.

Original languageEnglish
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume62
Issue number4
Pages (from-to)507-513
Number of pages7
ISSN0161-5505
DOIs
Publication statusPublished - Apr 2021

Keywords

  • peptide receptor radionuclide therapy
  • progressive meningioma
  • somatostatin receptor
  • treatment-refractory meningioma

Fingerprint

Dive into the research topics of 'Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual Patient Data Meta-analysis'. Together they form a unique fingerprint.

Cite this